

Clinical Trial Protocol

Iranian Registry of Clinical Trials

31 May 2026

Evaluating the Safety of Placenta Mesenchymal Stem Cells-derived Exosomes (HP-MSCs-derived Exosomes) in the Treatment of Steroid-Resistant Acute GVHD after Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Trial Phase I

Protocol summary

Study aim

Exosome therapy with exosomes derived from mesenchymal stem cells in acute steroid-resistant transplant disease

Design

This trial is a single-arm phase 1-2 interventional study (non-randomized and non-blinded) for 12 patients, the aim of which is to investigate the safety of exosomes derived from placental mesenchymal stem cells in transplant disease against the acute steroid-resistant host.

Settings and conduct

This study is a single-group clinical trial to evaluate the safety of exosomes derived from placental mesenchymal stem cells in the laboratory for the treatment of transplant disease against acute steroid-resistant host in Taleghani Hospital of Shahid Beheshti University of Medical Sciences.

Participants/Inclusion and exclusion criteria

Inclusion: Grade II to IV acute Graft Versus Host Disease (aGVHD) patients, poor response to corticosteroids, signed written informed consent Exclusion: Recurrence of the main disease (cancer), use of Infliximab, Infections

Intervention groups

Routine treatment and injection of one unit of exosome derived from mesenchymal stem cells is almost equivalent to the number of exosome particles, which is 10 to the power of 11, prepared from every 10 to the power of 8 cells, which is done at the same rate in the recipient group weighing 50 to 80 kg.

Main outcome variables

Recurrence of acute Graft Versus Host Disease (aGVHD) and infection; Overall Remission Rate; Progression-free survival; Duration of Response

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20200413047063N6**

Registration date: **2025-05-24, 1404/03/03**

Registration timing: **registered_while_recruiting**

Last update: **2025-05-24, 1404/03/03**

Update count: **0**

Registration date

2025-05-24, 1404/03/03

Registrant information

Name

Masoud Soleimani

Name of organization / entity

Tarbiat Modares University

Country

Iran (Islamic Republic of)

Phone

+98 21 8288 4508

Email address

soleimani.masoud@gmail.com

Recruitment status

recruiting

Funding source

Expected recruitment start date

2024-12-30, 1403/10/10

Expected recruitment end date

2026-12-31, 1405/10/10

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluating the Safety of Placenta Mesenchymal Stem Cells-derived Exosomes (HP-MSCs-derived Exosomes) in the Treatment of Steroid-Resistant Acute GVHD after Allogeneic Hematopoietic Stem Cell Transplantation: Clinical Trial Phase I

Public title

Exosome therapy in steroid-resistant acute Graft Versus Host Disease (GVHD) patients

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

Patients diagnosed with grade II to IV acute Graft versus host disease (GVHD) whose response to treatment with corticosteroids equal to or more than 2 milligrams per kilogram is poor, and the disease symptoms progress in three days or have stable disease for five days Patients over 18 years old Patients of both sexes Signed written informed consent

Exclusion criteria:

Patients who have recurrence of the main disease (cancer) Patients who, in the differential diagnosis of clinical symptoms, have causes other than acute graft versus host disease (aGVHD) indicating the patient, such as patients with symptoms Sinusoidal Obstruction Syndrome (SOS), maculopapular skin rashes with drug or viral causes or Engraftment Syndrome, viral diarrheas, etc Patients who have been prescribed Infliximab The presence of an active uncontrolled infection, including a significant bacterial, fungal, viral or parasitic infection that requires treatment Presence of recurrent primary malignancy, or those treated for recurrence after Hematopoietic Cell Transplantation (HCT), or those who may require rapid removal of immunosuppression as pre-emergency treatment of primary recurrence Have unresolved venous occlusion disease Patients who have any underlying or current medical or psychiatric problems that the researcher thinks may be a disorder (uncontrolled infection, cardiovascular failure, and pulmonary pressure) Patients who have any allergy to blood products

Age

From **18 years** old to **65 years** old

Gender

Both

Phase

1

Groups that have been masked

No information

Sample size

Target sample size: **12**

Randomization (investigator's opinion)

Not randomized

Randomization description**Blinding (investigator's opinion)**

Not blinded

Blinding description**Placebo**

Not used

Assignment

Single

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics Committee of Shahid Beheshti University of Medical Sciences

Street address

Tehran Province, Tajrish, Velenjak, 7th Floor, Bldg No.2 SBUMS, Arabi Ave

City

Tehran

Province

Tehran

Postal code

1985717443

Approval date

2024-05-12, 1403/02/23

Ethics committee reference number

IR.SBMU.REC.1403.011

Health conditions studied**1****Description of health condition studied**

Acute steroid-resistant graft-versus-host disease

ICD-10 code

D89.810

ICD-10 code description

Acute graft-versus-host disease

Primary outcomes**1****Description**

Recurrence of acute Graft Versus Host Disease (aGVHD) and infection

Timepoint

7, 21 and 28 days after injection

Method of measurement

History, Physical exam, and lab test

2**Description**

Overall Remission Rate (ORR)

Timepoint

7, 21 and 28 days after injection

Method of measurement

Assessed using the Glusburg (based on GvHD grade)

Secondary outcomes

1

Description

Progression-free survival (PFS)

Timepoint

48 weeks after exosome infusion

Method of measurement

Assessed using the Graft-versus-Host Disease Working Committee

2

Description

Duration of Response (DOR)

Timepoint

48 weeks after exosome infusion

Method of measurement

Assessed using the Graft-versus-Host Disease Working Committee

Intervention groups

1

Description

Intervention group: Patients diagnosed with grade II to IV acute Graft Versus Host Disease (aGVHD), whose response to treatment with corticosteroids equal or more than 2 milligram per kilogram (mg/kg) is poor and symptoms progress in three days or stable disease for five days, after informed written consent will be included in the study. The diagnosis of Steroid resistant acute graft versus host disease (SR-aGVHD) is based on the diagnosis, grading and staging of aGVHD according to clinical observations and criteria suggested by the International Blood and Bone Marrow Transplant Research Center. Exosome derived from placenta mesenchymal stem cells from donors after obtaining a written consent from the donor, several tests are performed for the absence of contamination. Then the mesenchymal cells are separated under sterile conditions (Good Manufacturing Practices (GMP) grade) and after the characteristic finding in sterile vials will be transferred to the hospital and will be used as an intravenous injection for patients. In each exosome injection, 1 unit of human placenta -derived mesenchymal stem cell exosome (HP-MSC-EXO) is approximately equivalent to the number of exosome particles, which is prepared from 101 x 108 cells, which is administered in the same amount of HP-MSC-EXO in the recipient group weighting 50 to 80 kilogram. The dose of exosome based on studies is 50 microgram per milliliter (µg/mL) and is equivalent to 250-300 milligram of exosome in each vial. Agonists of H1 and H2 receptors are prescribed to prevent allergic reactions before injection and patients are constantly monitored for 2 hours. Exosome injection is done in the form of three doses on the first day after an interval of 8 hours (TDS)

and maintenance injection is done daily for 5 days, which dose will be done based on a pilot study conducted in Taleghani Hospital. In this group, the prescription of other treatment protocols, especially Infliximab, is not allowed under any circumstances, and if prescribed, the patient will be excluded from the study. Until the complete failure of the treatment, the prescription of other treatment protocols, especially Infliximab, is prohibited.***The therapeutic intervention method and scientific history and the theoretical basis of the method and its research history as well as the possibility of side effects are accurately and transparently informed to the patient or his companions (often the companions of the patient due to the bad condition of the patients) and the relevant therapeutic intervention it is done with their consent. The information of the patients is collected every day by the researcher who collects the information by filling out a special form. The method of collecting information is based on talking to the patient in his clinic and examining the file to check the symptom registration forms and the results of clinical tests.***Patients assessment in terms of recurrence of aGVHD and infection, complications of cell therapy (safety), recurrence of the disease at intervals of 7+, 21+ and 28+ days after the first exosome injection. Patients are evaluated based on Glusburg criteria (based on GvHD grade) at intervals of +14, +21 and +28 days after the first injection. All patients who receive exosome should wash the route of exosome injection with distilled water immediately before and after injection. Vital signs of patients are constantly checked; Especially, the symptoms one hour after drug injection and as an investigation of the possible effects of the drug are recorded in the results. Any unwanted complication or unusual event is recorded so that it can be recorded in the results if a possible complication occurs. If the condition of the recipient of exosome worsens, the patient will be excluded from the study and the patient will be a candidate for drug or cell therapy.

Category

Treatment - Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Omid cell and tissue tech

Full name of responsible person

Masoud Soleimani

Street address

West Qabadian St.

City

Tehran

Province

Tehran

Postal code

1968917313

Phone

+98 912 287 5993

Email

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Omid cell and tissue tech

Full name of responsible person

Masoud Soleimani

Street address

West Qabadian St.

City

Tehran

Province

Tehran

Postal code

1968917313

Phone

+98 912 287 5993

Email

soleim_m@modares.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Omid cell and tissue tech

Proportion provided by this source

80

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Persons

2

Sponsor

Name of organization / entity

Shahid Beheshti University of Medical Sciences

Full name of responsible person

Abbas hajifathali

Street address

Shahid Beheshti University of Medical Sciences, Arabi St., Student Blvd., Valenjak, Tehran

City

Tehran

Province

Tehran

Postal code

1985717443

Phone

+98 912 340 7482

Email

a.hajifathali@sbmu.ac.ir

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Shahid Beheshti University of Medical Sciences

Proportion provided by this source

20

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Persons

Person responsible for general inquiries

Contact

Name of organization / entity

Omid cell and tissue tech

Full name of responsible person

Masoud Soleimani

Position

Professor

Latest degree

Ph.D.

Other areas of specialty/work

Hematology

Street address

West Qabadian St.

City

Tehran

Province

Tehran

Postal code

1968917313

Phone

+98 912 287 5993

Email

soleim_m@modares.ac.ir

Person responsible for scientific inquiries

Contact

Name of organization / entity

Omid cell and tissue tech

Full name of responsible person

Masoud Soleimani

Position

professor

Latest degree

Ph.D.

Other areas of specialty/work

Hematology

Street address

West Qabadian St.

City

Tehran
Province
Tehran
Postal code
1968917313
Phone
+98 912 287 5993
Email
soleim_m@modares.ac.ir

Person responsible for updating data

Contact

Name of organization / entity
Shahid Beheshti University of Medical Sciences
Full name of responsible person
Abbas hajifathali
Position
Professor
Latest degree
Ph.D.
Other areas of specialty/work
Hematology
Street address
Shahid Beheshti University of Medical Sciences, Arabi
St., Student Blvd., Valenjak, Tehran
City
Tehran
Province
Tehran

Postal code
1985717443
Phone
+98 912 340 7482
Email
a.hajifathali@sbmu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available